After failing with its initial programs, TargeGen progressed its innovative JAK2 inhibitor from the discovery phase into clinical trials in record time, capitalizing on intense interest in the JAK2 marker within the pharmaceutical industry. Sanofi is currently developing TargeGen’s lead compound for the treatment of myelofibrosis and polycythemia vera, debilitating blood disorders for which there is a very large unmet medical need.

Sanofi acquired TargeGen in 2010 for up to $560 million in upfront and milestone payments.